“Porem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.”
Gondi received BS and MS degrees in Pharmacy from Kakatiya and Andhra universities in India, Ph.D. in Medicinal Chemistry from the University of Florida, and post-doctoral training in drug metabolism and pharmacokinetics at the Medical University of South Carolina.
Gondi is a diplomate of American Board of Toxicology. Most recently Gondi was Senior Vice President – Nonclinical R&D at Bristol Myers Squibb. Gondi’s group at BMS was comprised of nonclinical safety assessment, drug metabolism & pharmacokinetics, nonclinical/clinical bioanalysis, discovery pharmaceutics and veterinary sciences, with responsibility for the entire BMS R&D portfolio comprised of small molecule chemical entities, biotherapeutics and cell therapies. Prior to BMS Gondi had worked at Celgene (2012-2019 as Head of Nonclinical Development), Abbott and Amgen in scientific and leadership roles of increasing responsibility.
Over the last 30 years, Gondi has made important scientific contributions to the discovery and development of multiple therapeutic agents including Norvir®, Kaletra®, Plenaxis® Sensipar®, Pomalyst® and Otezla®. He had corporate leadership roles at both Celgene and BMS for the last two decades with responsibilities for product advancement strategies and resolution of scientific issues.
He has published extensively in peer-reviewed journals, and co-authored PhRMA perspective papers. He is a co-inventor of multiple drug candidates including HIV PI Kaletra® (lopinavir in combination with ritonavir). Gondi is currently consulting for biopharma companies and non-profit drug discovery and development organization
